New research model for Cancer Research UK following £300M drop in income
Cancer Research UK is planning to become a leaner, more focused organisation following the impact of COVID-19 on its fundraising income.
The charity is making difficult decisions to reduce how much it spends on beating cancer, its operations and the number of staff following an anticipated £300 million decline in fundraising income over the next three years but is more focussed than ever on staying at the forefront of the global fight against cancer.
The charity plans to rebuild and find new opportunities to continue to make an impact for people with cancer. There will be a continued focus on world-class research and shaping the UK’s science ecosystem, and a commitment to influencing and providing excellent information across cancer prevention, diagnosis and treatment.
But due to the projected drop in income, of £160 million this year (30%) and £300 million over three years, the charity needs to make tough choices about where and how it spends its money. There will be a greater focus on investing strategically for the future, whilst contracting in other areas amidst continued financial uncertainty.
Cancer Research UK is calling on the UK government to help find a solution to this funding gap. The transition to a new funding model will be phased carefully to minimise the impact on the research community and existing portfolio. The commitment to maximising research impact remains, and the charity will continue to back the best researchers around the world
Michelle Mitchell, Chief Executive at Cancer Research UK said: “We’re living through a global crisis unlike any other and, as it’s unfolded, it’s become clear that there’ll be a huge economic impact for years to come. As the world’s leading cancer charity dedicated to saving lives through research, we must always focus on delivering our pioneering work into the prevention, diagnosis and treatment of cancer.
“We made some very difficult decisions early on to mitigate the impact on our work; we moved all of our staff to 80% pay, furloughed 60% of staff, and cut £44 million from our research. But it is with a heavy heart that I can confirm we will have to reduce the size of our workforce, and make significant cuts to our research spend, as a result of the situation we find ourselves in. With such a significant shortfall in income, we cannot afford to keep spending at the same levels. But that doesn’t make those decisions any easier. We’re keeping our dedicated, hard-working staff up to date on developments as we have them, and their professionalism throughout this period has been hugely appreciated.
“I am confident that through our world-leading research, information and influencing, we will continue to make transformative steps in the prevention, diagnosis and treatment of cancer. This plan sets the direction for a new phase in the life of Cancer Research UK and will help us respond to the changed world, quicker than we’ve ever done before. We will emerge a streamlined charity, but still with a resolute drive for impact. Together, we will still beat cancer and realise our ambition to improve cancer survival to 3 in 4 by 2034.”
Avacta collaboration offers update on Affimer therapy for COVID-19 READ MORE
CatalYm to present data on targeting novel checkpoint GDF-15 for immunotherapy of cancer at AACR Annual Meeting READ MORE
Research highlights public desire for animal alternatives in research READ MORE
Cancer vaccine shows promising signs READ MORE
New drug could treat blood cancer and solid tumours READ MORE
Top Ten UK organisations for animal research announced READ MORE
Immune system could be trained to spot drug-resistant cancers READ MORE
Researchers discover cell communication mechanism that drives cancer adaptation READ MORE
Cancer Research UK, University of Southampton and Touchlight Genetics develop head and neck cancer vaccine READ MORE
Cancer Research UK and AstraZeneca's antibody maturation yields high-affinity arginase 2 antibody READ MORE